Galderma has reported the positive findings of two phase IV clinical studies of its newest Restylane dermal filler products, Restylane Refyne and Restylane Defyne.
Presented at the recent Aesthetic and Anti-Ageing Medicine Annual World Congress, data from the Natural Expression study found that naturalness in facial expressions was at least maintained in 95 percent of subjects receiving these fillers.
“Galderma has reported new clinical study data showing the practical benefits offered by its newest Restylane dermal filler products.“
Additionally, results from the Dynamic Strain study found that 83 percent of subjects experienced enhanced attractiveness, a younger look and a retained natural aesthetic after receiving Restylane Refyne and Restylane Defyne injections.
Both products are designed for the treatment of moderate to severe facial wrinkles and folds, including nasolabial folds or laugh lines, in patients over the age of 21.
They have been manufactured with XpresHAn Technology to produce gels that offer a range of flexibility and support for varied patient needs.
Johannes Baensch, chief scientific officer of Nestle Skin Health, said the studies "provide scientific evidence that our XpresHAn Technology addresses a major concern for patients who fear looking unnatural by delivering natural-looking results that are maintained during everyday and dynamic expressions".
With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Consumer